<?xml version="1.0" encoding="UTF-8"?><experiments api-version="3" api-revision="091015" version="3.0" revision="091015" total="1" total-samples="264" total-assays="132"><experiment><id>217137</id><accession>E-GEOD-21501</accession><secondaryaccession>GSE21501</secondaryaccession><name>A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma</name><releasedate>2010-07-18</releasedate><lastupdatedate>2014-05-01</lastupdatedate><organism>Homo sapiens</organism><experimenttype>transcription profiling by array</experimenttype><description><id/><text>A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma Pancreatic ductal adenocarcinoma (PDAC), comprising over 90% of all pancreatic cancers, remains a lethal disease with an estimated 232,000 new cases, 227,000 deaths per year worldwide, and a less than 5% five-year survival rate. Currently the standard of care for the 20% of patients with localized disease is surgery followed by chemotherapy, and in some cases radiation. Unfortunately despite the use of adjuvant therapy, median survival remains at best 23 months. It is important to note however, that up to 27% of patients with resected PDAC can survive for five years. However, in these studies examining actual long-term survivors, only two have found that adjuvant therapy was associated with improved survival. In addition, randomized controlled trials of gemcitabine-based chemotherapy demonstrate an improvement in median survival of at best 3 months. One possible conclusion from these studies is that tumor biology dictates outcome and that our current adjuvant therapy has only a modest impact on altering a patient's course.Hypothesizing that the dismal outcome of patients with localized disease is due to the presence of micrometastasic disease, current clinical investigation has focused on preoperative or neoadjuvant therapy. This approach, where patients who cannot tolerate the stress of therapy or develop metastatic disease during treatment are spared surgery, has demonstrated an overall survival of 34 months in this highly selected patient population. Therefore the ability to select patients who would most benefit from a neoadjuvant approach may be important. One way to do this is to define a prognostic gene signature that can identify patients with more aggressive tumor biology upfront. reference x sample The 30 Nebraska and UNC samples were not analyzed with clinical data so it is not provided. One of the PE samples is missing some clinical data.</text></description><provider><contact>Jen Jen Yeh</contact><role>submitter</role><email>jen_jen_yeh@med.unc.edu</email></provider><provider><contact>Jen J Yeh</contact><role/><email/></provider><provider><contact>Jeran K Stratford</contact><role/><email/></provider><bibliography><accession>20644708</accession><authors>Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, Hollingsworth MA, Perou CM, Yeh JJ</authors><title>A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma.</title><doi>10.1371/journal.pmed.1000307</doi></bibliography><samplecharacteristic><category>BioSourceProvider</category><value>Johns Hopkins Medical Institutions</value><value>NorthShore University HealthSystem</value><value>Northwestern Memorial Hospital</value><value>Stratagene (Part # 74000_41, lot 1130623)</value><value>University of Nebraska Medical Center Rapid Autopsy Pancreatic Program</value><value>Yeh Lab-UNC-CH</value></samplecharacteristic><samplecharacteristic><category>n stage</category><value>1</value></samplecharacteristic><samplecharacteristic><category>Organism</category><value>Homo sapiens</value></samplecharacteristic><samplecharacteristic><category>organism part</category><value>Patient Primary Pancreatic Tumor</value><value>Stratagene Human reference RNA</value></samplecharacteristic><samplecharacteristic><category>os event</category><value>1</value></samplecharacteristic><samplecharacteristic><category>os time</category><value>1</value><value>10</value><value>11</value><value>13</value><value>14</value><value>15</value><value>16</value><value>17</value><value>18</value><value>19</value><value>2</value><value>20</value><value>21</value><value>22</value><value>23</value><value>24</value><value>25</value><value>26</value><value>29</value><value>3</value><value>30</value><value>31</value><value>33</value><value>35</value><value>4</value><value>41</value><value>42</value><value>43</value><value>46</value><value>49</value><value>52</value><value>54</value><value>55</value><value>59</value><value>6</value><value>7</value><value>8</value></samplecharacteristic><samplecharacteristic><category>reference</category><value>Stratagene Human reference RNA</value></samplecharacteristic><samplecharacteristic><category>risk group</category><value>High Risk</value><value>Low Risk</value></samplecharacteristic><samplecharacteristic><category>t stage</category><value>1</value><value>2</value><value>3</value><value>4</value></samplecharacteristic><samplecharacteristic><category>tumor type</category><value>12R2585B Mix Pancreas (20/80/0)</value><value>12R2587.1Mix(50%N) P</value><value>12R2587.2Mix(80%N) P</value><value>12R2685T Panc</value><value>13R2778 Mix(90%N) Panc</value><value>13R2778Rpt</value><value>2R14B Mix Pancreas (KV:Tu in LN) 30/60/10</value><value>3R261B T Panc</value><value>4R678B2 Mix Panc</value><value>5R913Mix Pancreas 50/30/20</value><value>7R1353Brpt Panc 70/30/0</value><value>8R1405Mix 20/60/20</value><value>9R1701.2P Mix</value><value>9R1701B Mix Panc (10/90/0)</value><value>9R1703Mix Pancreas</value><value>P01-0505B</value><value>P03-0175AB</value><value>P04-0234B</value><value>P04-0316B</value><value>P04-0379B</value><value>P05-0175B</value><value>P05-0268B</value><value>P06-0925B</value><value>P06-1118B</value><value>P06-1366B</value><value>P06-1552B</value><value>P070710B</value><value>P071118B</value><value>P071155B</value><value>P99-0320B</value><value>Pancreatic Tumor</value><value>Pancreatic Tumor.</value></samplecharacteristic><experimentalvariable><name>BIOSOURCEPROVIDER</name><value>Johns Hopkins Medical Institutions</value><value>NorthShore University HealthSystem</value><value>Northwestern Memorial Hospital</value><value>Stratagene (Part # 74000_41, lot 1130623)</value><value>University of Nebraska Medical Center Rapid Autopsy Pancreatic Program</value><value>Yeh Lab-UNC-CH</value></experimentalvariable><experimentalvariable><name>ORGANISM PART</name><value>not specified</value><value>Patient Primary Pancreatic Tumor</value><value>Stratagene Human reference RNA</value></experimentalvariable><experimentalvariable><name>OS TIME</name><value>1</value><value>10</value><value>11</value><value>13</value><value>14</value><value>15</value><value>16</value><value>17</value><value>18</value><value>19</value><value>2</value><value>20</value><value>21</value><value>22</value><value>23</value><value>24</value><value>25</value><value>26</value><value>29</value><value>3</value><value>30</value><value>31</value><value>33</value><value>35</value><value>4</value><value>41</value><value>42</value><value>43</value><value>46</value><value>49</value><value>52</value><value>54</value><value>55</value><value>59</value><value>6</value><value>7</value><value>8</value><value>not specified</value></experimentalvariable><experimentalvariable><name>RISK GROUP</name><value>High Risk</value><value>Low Risk</value><value>not specified</value></experimentalvariable><experimentalvariable><name>T STAGE</name><value>1</value><value>2</value><value>3</value><value>4</value><value>not specified</value></experimentalvariable><experimentalvariable><name>TUMOR TYPE</name><value>12R2585B Mix Pancreas (20/80/0)</value><value>12R2587.1Mix(50%N) P</value><value>12R2587.2Mix(80%N) P</value><value>12R2685T Panc</value><value>13R2778 Mix(90%N) Panc</value><value>13R2778Rpt</value><value>2R14B Mix Pancreas (KV:Tu in LN) 30/60/10</value><value>3R261B T Panc</value><value>4R678B2 Mix Panc</value><value>5R913Mix Pancreas 50/30/20</value><value>7R1353Brpt Panc 70/30/0</value><value>8R1405Mix 20/60/20</value><value>9R1701.2P Mix</value><value>9R1701B Mix Panc (10/90/0)</value><value>9R1703Mix Pancreas</value><value>not specified</value><value>P01-0505B</value><value>P03-0175AB</value><value>P04-0234B</value><value>P04-0316B</value><value>P04-0379B</value><value>P05-0175B</value><value>P05-0268B</value><value>P06-0925B</value><value>P06-1118B</value><value>P06-1366B</value><value>P06-1552B</value><value>P070710B</value><value>P071118B</value><value>P071155B</value><value>P99-0320B</value><value>Pancreatic Tumor</value><value>Pancreatic Tumor.</value></experimentalvariable><arraydesign><id>11853</id><accession>A-AGIL-28</accession><name>Agilent Whole Human Genome Microarray 4x44K 014850 G4112F (85 cols x 532 rows)</name><count>132</count><legacy_id>1316855037</legacy_id></arraydesign><protocol><id>576558</id><accession>P-GSE21501-1</accession></protocol><protocol><id>576559</id><accession>P-GSE21501-2</accession></protocol><protocol><id>576561</id><accession>P-GSE21501-3</accession></protocol><protocol><id>576562</id><accession>P-GSE21501-4</accession></protocol><protocol><id>576560</id><accession>P-GSE21501-5</accession></protocol><protocol><id>576556</id><accession>P-GSE21501-6</accession></protocol><protocol><id>576557</id><accession>P-GSE21501-7</accession></protocol><bioassaydatagroup><id/><name>normalization</name><bioassaydatacubes>132</bioassaydatacubes><arraydesignprovider/><dataformat>normalization</dataformat><bioassays>132</bioassays><isderived>0</isderived></bioassaydatagroup><bioassaydatagroup><id/><name>processedData</name><bioassaydatacubes>132</bioassaydatacubes><arraydesignprovider/><dataformat>processedData</dataformat><bioassays>132</bioassays><isderived>0</isderived></bioassaydatagroup></experiment></experiments>